Quarterly ResultMay 7, 2026, 07:42 AM
ImmunityBio Q1 Revenue +168% to $44.2M; Net Loss $(632.8)M
AI Summary
ImmunityBio reported a significant increase in total revenue for Q1 2026, reaching $44.2 million, primarily driven by U.S. sales of ANKTIVA. However, the company's net loss widened substantially to $(632.8) million, largely due to significant non-cash expenses from changes in the fair value of warrant liabilities and a related-party convertible note. The company also raised $223.9 million through financing activities, including equity offerings and proceeds from the RIPA, but noted substantial doubt about its ability to continue as a going concern without additional funding.
Key Highlights
- Total revenue surged 167.6% to $44.2 million in Q1 2026, up from $16.5 million in Q1 2025.
- Net loss attributable to common stockholders significantly widened to $(632.8) million in Q1 2026, from $(129.6) million in Q1 2025.
- Diluted net loss per share was $(0.62) for Q1 2026, compared to $(0.15) for Q1 2025.
- Non-cash expenses included a $(295.4) million change in fair value of warrant liabilities and $(236.6) million for related-party convertible note.
- Cash and cash equivalents increased to $205.2 million as of March 31, 2026, from $88.3 million at December 31, 2025.
- Net cash provided by financing activities was $223.9 million in Q1 2026, including $102.2 million from equity offerings.
- The company recorded a $7.4 million charge for the write-off of a convertible note receivable.
- Management noted substantial doubt about the company's ability to continue as a going concern without additional funding.
Price Impact
More from IBRX